02 Chairmans Statement I am pleased to report another year of strong financial and strategic performance for Croda.
This achievement in tough economic conditions demonstrates the resilience of our Consumer Care and Performance Technologies businesses, with both sectors reporting higher profits and a further improvement in margins.
Our progress reects our strategic focus on sustainable growth through continued product innovation in niche markets and increasing investment in new technologies and emerging markets, particularly in Asia and Latin America.
In 2012, small acquisitions have added exciting new technologies which will enhance our existing capabilities in key areas.
Turnover from continuing operations increased by 2.3% to Pre-tax profit from continuing operations rose by 6.6% to 1,051.9m 253.2m 2011: 1,028.0m 2011: 237.5m Full Year Results Acquisitions Croda again achieved record sales, margins and profits in 2012.
While the main driver of Crodas future growth is expected to be innovation Turnover from continuing operations increased by 2.3% to 1,051.9m generated from within the Group, an important part of our strategy is to 2011: 1,028.0m and operating profit grew by 7.4% to 255.4m enhance our progress through the acquisition of complementary new 2011: 237.7m, a return on sales of 24.3% 2011: 23.1%.
by strong underlying progress in the two principal business sectors of In July 2012, we acquired Istituto di Ricerche Biotecnologiche IRB in Italy, Consumer Care and Performance Technologies.
the global leader in plant stem cell technology, for a total consideration of Pre-tax profit from continuing operations rose by 6.6% to 253.2m 7.7m.
The acquisition has been successfully integrated within our Sederma 2011: 237.5m, and earnings per share on the same basis increased skin care actives business and we have received a very encouraging by 8.2% to 130.0p 2011: 120.1p.
response to its unique capabilities from our existing customers, with one major multinational client already incorporating an IRB product into a new Sector Performance global product formulation.
Consumer Care sales increased by 2.6% over the year to 586.4m 2011: 571.4m, despite some weakness in the third quarter, while In December 2012, we acquired the trade and assets of Innovachem operating profit rose by 8.3% to 185.4m 2011: 171.2m.
The return on LLC in the US for a total consideration of US$2.8m.
This acquisition is an sales of 31.6% 2011: 30.0% was a new record for the Group, driven by excellent strategic fit for our Personal Care business, adding a number exciting new product launches.
We achieved profit growth in all three of exciting new patented product lines and technologies to our existing business areas, with Crop Care making the strongest progress.
Personal portfolio and enhancing its ability to service customers around the world.
Care and Health Care made modest progress despite the tough market conditions for consumer products in Europe.
Disposals In November 2012, we sold our Cremona business in Italy, completing In our new Performance Technologies reporting segment, sales rose the disposal of the last remaining fatty acid and glycerine plant that we by 2.5% to 382.8m 2011: 373.6m and operating profit increased acquired with Uniqema in 2006.
These undifferentiated technologies are by 8.0% to 59.7m 2011: 55.3m.
Return on sales improved to 15.6% not Crodas core competence, but our employees had worked tirelessly to 2011: 14.8%, representing good progress towards our medium term deliver value from the site and we were delighted to conclude its sale to target of 20%.
All business areas achieved underlying sales growth and an Italian business.
Polymer Additives, Geo Technologies and Home Care also made strong profit progress, partially offset by slight declines in Lubricants and Coatings Dividend & Polymers due to the weakness of their European markets, particularly Croda is a highly cash generative business, allowing us to maintain a in the automotive sector.
strong dividend policy while also funding significant capital investment in the business and making appropriate bolt-on acquisitions, and at the Industrial Chemicals sales were 0.4% lower at 82.7m 2011: 83.0m same time reducing net debt.
This reflected high raw material prices and competitive commodity and textile markets, though we did see an improving trend in the second half of the year.
03 BUSINESS REVIEW CORPORATE GOVERNANCE FINANCIAL STATEMENTS OTHER INFORMATION Economic uncertainty continues, particularly in Europe, but we have made an encouraging start to the year and the Board is confident that Croda will make further progress in 2013.
In 2011, we announced our intention to increase our dividend payout to between 40% and 50% of sustainable earnings, resulting in a 57.1% increase in our total dividend for 2011.
Building on this new base, the Board is now recommending an increased final dividend of 32.75p 2011: 30.25p.
Together with the interim dividend of 26.75p 2011: 24.75p paid in October 2012, this makes a total dividend of 59.5p 2011: 55.0p, an increase of 8.2% for the year.
This maintains the payout ratio around the middle of our target range at 46%.
Subject to future trading and the maintenance of a prudent approach to cash and balance sheet management, Croda expects to maintain its progressive dividend policy in the years ahead.
Outlook Economic uncertainty continues, particularly in Europe, but we have made an encouraging start to the year and the Board is confident that Croda will make further progress in 2013.
